Wegovy 1.25 mg: the dose that almost nobody stays on

Why 1.25 mg appears in semaglutide searches, and which medicine it actually belongs to

Semaglutide has two distinct UK product identities, and the 1.25 mg figure is where they most often get tangled. Ozempic, also made by Novo Nordisk, uses a dose ladder designed for blood-sugar management in type 2 diabetes: 0.25 mg as an introductory step, then 0.5 mg, then 1 mg, with 1.25 mg and 2 mg available as additional steps in some prescribing situations. That 1.25 mg step has crept into weight-loss discussions because the active molecule is identical to Wegovy's. The NHS medicines page for semaglutide explains the distinction clearly: the licensed indication, the product name and the dose schedule all differ between the two formulations.

Wegovy's schedule was built specifically around appetite regulation and body-weight endpoints. The STEP 1 trial, published in the New England Journal of Medicine, tested semaglutide 2.4 mg weekly over 68 weeks and found an average body-weight reduction of around 15 percent, a figure that informed the licensed maintenance dose. No equivalent weight-loss trial used 1.25 mg as a target dose, which is part of why it never entered the Wegovy schedule, and why the licensed journey instead begins at the Wegovy 0.25 mg starting dose before titrating upward through a series of carefully spaced steps.

If a seller is offering semaglutide for weight loss at 1.25 mg, that product is either Ozempic (not licensed for this use) or something unverified. The GPhC pharmacy register lets you confirm in under a minute whether any online pharmacy is legitimately registered in the UK, search the provider's name or registration number before you order anything.

The actual Wegovy dose ladder, including the 7.2 mg approval in 2026

Understanding the real schedule makes it much easier to spot when something looks wrong. Wegovy treatment starts at 0.25 mg weekly, purely to let the body adjust, nausea and other gastrointestinal effects are far less likely when the dose rises slowly. From there, a prescriber typically moves the dose upward in roughly four-week intervals: 0.5 mg, then 1.0 mg, then 1.7 mg, before reaching the standard 2.4 mg maintenance dose. If you want to understand each stage in detail, the full breakdown of Wegovy doses covers what changes at each rung and why the pace of titration is set by clinical response rather than a fixed calendar.

A significant addition came in early 2026. On 14 April 2026, the MHRA approved a dedicated single-dose 7.2 mg pen, one pre-set weekly injection for adults with a BMI of 30 or above. Trials at this higher dose reported an average weight reduction of around 20.7 percent over 72 weeks, which narrows the gap considerably with tirzepatide's results. The 7.2 mg step is the maximum; starting dose remains 0.25 mg regardless of how high the eventual target is.

For context on how this compares to the earlier dose options, the Wegovy doses by strength page sets out the full picture. And if cost is a consideration alongside clinical suitability, Wegovy pricing in the UK explains what private treatment typically involves, a useful reference before you speak to a prescriber.

Side effects along the titration pathway, what the evidence says about lower doses

One reason the schedule exists in its current form is that side effects cluster around dose changes, not around any single dose being inherently risky. The STEP 1 trial found that gastrointestinal effects (nausea, loose stools, indigestion and similar) were most common in the weeks immediately following a step up, and typically settled as the body adapted. At the 0.25 mg and 0.5 mg stages, many people notice very little at all.

The profile at 0.25 mg specifically is largely about tolerability rather than effect: the dose is too low to drive meaningful weight loss, which is why the schedule moves on from it. The same logic applies to the 1.0 mg step, a real licensed stage, but still a waypoint rather than a destination for most patients.

Urgent medical attention is needed for severe, persistent abdominal pain that radiates toward the back, with or without vomiting, this can signal acute pancreatitis, highlighted in a January 2026 MHRA Drug Safety Update on GLP-1 medicines. Suspected side effects can be reported through the MHRA's Yellow Card scheme. Lesser GI symptoms (nausea, burping, constipation) are common and generally manageable; your prescriber and the Patient Information Leaflet are the right places to discuss them.

What to do if you are currently on a semaglutide dose that does not match the Wegovy schedule

If your current prescription lists a dose not on the licensed Wegovy ladder (1.25 mg being the most commonly queried) it is worth checking the medicine name on the packaging and the prescribing indication. Ozempic pens look similar to Wegovy pens; the label will tell you which product you have received. A prescriber should be able to clarify immediately, and if you received the product from an online source you cannot verify, that is also worth raising.

For people exploring what licensed weight-loss treatment looks like (whether injectable semaglutide, tirzepatide, or the new oral Wegovy tablet) the weight-loss treatment overview is a good starting point. Our clinical team, including independent prescriber Mostafa Damghani, reviews consultations personally; there is no algorithm involved. If you are ready to find out whether Wegovy is appropriate for you, check your eligibility with a free consultation, a prescriber will go through your full medical picture before anything is prescribed.